Biotechnology

YUMAB GmbH, a spin-off from University of Braunschweig, offers products, services and technologies for the generation and engineering of recombinant, monoclonal and human antibodies. Founders and employees of YUMAB provide their experience of more than 20 years for customized solutions in this field.
YUMAB’s advanced in vitro selection technology based on phage display and very large proprietary universal human antibody gene libraries. The generation of novel custom antibodies, so-called “Yumabs”, is efficient and fast (<6 weeks) und does not require the immunization of animals.
“Yumabs” are distinguished by tailor-made and standardized properties as well as highest quality and purity. “Yumabs” have been proven in many applications in science and industry. YUMAB offers additional solutions for the development and improvement of therapeutic antibodies (e.g. affinity maturation, humanization) and the construction of antibody gene libraries.

Recombinant human antibodies & antibody engineering

What we offer

YUMAB GmbH offers products, services and technologies for generation and engineering of human, recombinant, monoclonal antibodies. Founders and employees provide >20 years experience in this field for customized solutions. YUMAB’s advanced in vitro selection technology (phage display) and very large universal human antibody gene libraries allow efficient and fast generation of novel custom antibodies, so-called “Yumabs”, without need of animal immunizations. “Yumabs” are distinguished by tailor-made and standardized properties as well as high quality and purity. “Yumabs” have been proven in all IgG standard applications. YUMAB provides solutions for development and improvement of therapeutic antibodies (e.g. affinity maturation, humanization) and construction of antibody gene libraries.

What we are looking for

YUMAB looks for partners and customers who require antibodies which are not accessible by conventional antibody generation in animals or who are interested in the broad range of new opportunities provided by recombinant antibody technology. Partners and customers can be from research or diagnostic or pharmaceutical industry. Partners may be interested in distribution or co-marketing.

Collaboration sought

  • Research & Development
  • Technical Co-operation
  • Joint Venture Agreement
  • Manufacturing Agreement
  • Licence Agreement
  • Commercial Agreement

Responsible

Mr Dr. Thomas Schirrmann

General Manager

back to list